Leukemia, Acute Promyelocytic (EA9131) Observational

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Confirmed to have a diagnosis of APL, which is defined as:
  • Positive t(15:17) by fluorescence in situ hybridization (FISH) or conventional karyotype
  • Positive promyelocytic leukemia/retinoic acid receptor PML/RAR alpha by polymerase chain reaction (PCR)
• Patients must accept treatment and supportive care guidelines
• Referrals must be made as early as possible but no later than 5 calendar days after ATRA therapy is initiated; consent can be obtained up till day 7 or earlier
• Co-management can be started as soon as referral is made including weekends; the physician at the outlying facility should make every effort to call the APL expert at the first suspicion of APL

To learn more, visit ClinicalTrials.Gov

Study Type

Observational

Principal Investigator(s)

Asim Pati, MD

Sponsor(s)

ECOG-ACRIN Cancer Research Group